论文部分内容阅读
对罕见病患者及其家庭来说,来自制度的保障——让所有患者能够买得起药,或许才是他们真正的福音如果不出意外,治疗四氢生物蝶呤(BH4)缺乏症的新药——“科望”(Kuvan)将于2011年第二季度在中国上市。中华预防医学会儿童保健分会新生儿
Perhaps it is their true blessing from the system to all those who are able to afford it - for unsurprising patients and their families - new drugs for the treatment of tetrahydrobiopterin (BH4) deficiency - “Kuvan” will be available in China in the second quarter of 2011. Chinese Society of Preventive Medicine child care branch of newborns